<DOC>
	<DOCNO>NCT00005588</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . It yet know regimen radiation therapy effective following surgery breast cancer . PURPOSE : Randomized phase III trial compare effectiveness two different regimen radiation therapy follow surgery treat woman early stage breast cancer .</brief_summary>
	<brief_title>Radiation Therapy After Surgery Treating Women With Early Stage Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine benefit radiotherapy schedule use fraction size large 2.0 Gy term normal tissue response , local-regional tumor control , quality life , economic consequence woman prescribe postoperative radiotherapy early stage breast cancer . OUTLINE : This randomize , multicenter study . Patients stratify accord center , type surgery ( mastectomy vs local excision ) , breast boost ( yes v ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive radiotherapy 5 time week 5 week total dose 50 Gy . - Arm II : Patients receive radiotherapy 5 time fortnight ( i.e. , Monday/Wednesday/Friday/Tuesday/Thursday/Monday , etc . ) 13 fraction 5 week total dose 41.6 Gy . - Arm III : Patients receive radiotherapy arm II total dose 39 Gy . A breast boost recommend arm patient microscopic evidence invasive situ cancer , within 1 mm , resection margin . These patient receive radiotherapy 5 fraction 1 week total boost dose 10 Gy . Quality life assess baseline 6 , 12 , 24 , 60 month . Patients follow annually 20 year . PROJECTED ACCRUAL : A total 2,010 patient ( 670 per arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive unilateral breast cancer consider operable T13 , N01 , M0 presentation Complete macroscopic excision tumor breast conserving surgery mastectomy No immediate breast reconstruction No requirement axillary radiotherapy great Level 1 axillary dissection great 10 lymph node remove Not enrol SECRAB OSCAR trial Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Prior neoadjuvant , primary medical , therapy allow provided subsequent surgery confirm complete macroscopic excision residual primary tumor Biologic therapy : Not specify Chemotherapy : At least 2 week since prior cytotoxic agent No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>